original ) (raw )Efficacy and pharmacodynamics of teicoplanin given daily during the first 3 days and then on alternate days for methicillin-resistant Staphylococcus aureus infections
Ricardo Durlach
Journal of Antimicrobial Chemotherapy, 1999
View PDFchevron_right
Pharmacodynamics of teicoplanin against MRSA
Piergiorgio Cojutti
Journal of Antimicrobial Chemotherapy, 2017
View PDFchevron_right
Influence of teicoplanin MICs on treatment outcomes among patients with teicoplanin-treated methicillin-resistant Staphylococcus aureus bacteraemia: a hospital-based retrospective study
Ming-hsun Lee
The Journal of antimicrobial chemotherapy, 2012
View PDFchevron_right
Relationship of teicoplanin MICs to treatment failure in teicoplanin-treated patients with methicillin-resistant Staphylococcus aureus pneumonia
Anna Ngo
Journal of Microbiology, Immunology and Infection, 2013
View PDFchevron_right
Teicoplanin levels in bone and joint infections: Are standard doses subtherapeutic?
Alison Taylor
Journal of Infection, 2007
View PDFchevron_right
Efficacy and safety of teicoplanin in infections caused by methicillin-resistant Staphylococcus aureus
Julian Palomino
Journal of Antimicrobial Chemotherapy, 1996
View PDFchevron_right
A multi-centre, phase IV study to evaluate the steady-state plasma concentration and serum bactericidal activity of a generic teicoplanin preparation
Duncan Cromarty
Southern African Journal of Infectious Diseases, 2015
View PDFchevron_right
Poor efficacy of teicoplanin in treatment of deep-seated staphylococcal infections
Nearchos Galanakis
European Journal of Clinical Microbiology & Infectious Diseases, 1988
View PDFchevron_right
Relationship Between Teicoplanin Use and Increase in Minimal Inhibitor Concentrations of Coagulase-Negative Staphylococci
Derya Keten
Gazi Medical Journal, 2014
View PDFchevron_right
Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis
J. Lambson , Adrian Brink , Guy Richards
International Journal of Antimicrobial Agents, 2008
View PDFchevron_right
Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria
Hjalmar Lagast
Antimicrobial Agents and Chemotherapy, 1986
View PDFchevron_right
Tolerability and plasma drug levels monitoring of prolonged subcutaneous teicoplanin treatment for bone and joint infections
Benoit Brunschweiler
Antimicrobial Agents and Chemotherapy, 2016
View PDFchevron_right
High-dose regimen to achieve novel target trough concentration in teicoplanin
Yoshio Takesue
Journal of Infection and Chemotherapy, 2014
View PDFchevron_right
A Review of Teicoplanin Used in the Prevention and Treatment of Serious Infections Caused by Gram-Positive Bacteria and Compared Its Effects with Some other Antibiotics
Faham Khamesipour
View PDFchevron_right
In vitro activity and human pharmacokinetics of teicoplanin
Bea Hendrickx
Antimicrobial Agents and Chemotherapy, 1984
View PDFchevron_right
In vitro studies of the pharmacodynamics of teicoplanin against Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecium
Inga Odenholt
Clinical Microbiology and Infection, 2003
View PDFchevron_right
Multicenter Prospective Observational Study of the Comparative Efficacy and Safety of Vancomycin versus Teicoplanin in Patients with Health Care-Associated Methicillin-Resistant Staphylococcus aureus Bacteremia
Salvatore Morgera
Antimicrobial Agents and Chemotherapy, 2014
View PDFchevron_right
Clinical efficacy of teicoplanin
Philippe Calain
European Journal of Clinical Microbiology & Infectious Diseases, 1990
View PDFchevron_right
Comparison of four methods for detection of teicoplanin resistance in methicillin-resistant Staphylococcus aureus
Rosalind Charlesworth
Journal of Antimicrobial Chemotherapy, 2006
View PDFchevron_right
Efficacy and safety of linezolid versus teicoplanin for the treatment of MRSA infections: a meta-analysis
Maomao Wu
The Journal of Infection in Developing Countries, 2018
View PDFchevron_right
Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose
Federico Pea
View PDFchevron_right
Experience with teicoplanin in the treatment of neonatal staphylococcal sepsis
Nilgun Kultursay
The Journal of international medical research
View PDFchevron_right
Three-Times Weekly Teicoplanin in the Outpatient Treatment of Acute Methicillin-Resistant Staphylococcal Osteomyelitis: A Pilot Study
Andrea Tramarin
Journal of Chemotherapy, 2002
View PDFchevron_right
Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction
Yoshio Takesue
European Journal of Clinical Microbiology & Infectious Diseases, 2016
View PDFchevron_right
Teicoplanin: a well-tolerated and easily administered alternative to vancomycin for Gram-positive infections in intensive care patients
J. Garaud
Intensive Care Medicine, 1994
View PDFchevron_right
Pharmacokinetics and bioavailability of a new formulation of tecoplanin following intrayenous and intramuscular administration to humans
Mark Eller
Journal of Pharmaceutical Sciences, 1991
View PDFchevron_right